ArticleToxicology research2025
The association of organophosphate flame retardants (OPFRs) exposure on omega-3 fatty acids metabolism: evidence derived from the United States general population.
Article in Toxicology research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
This study investigated the association between exposure to organophosphate flame retardants (OPFRs) and serum omega-3 fatty acid levels in the general U.S. population, using data from 1,350 adults in the 2011-2014 National Health and Nutrition Examination Survey (NHANES). OPFRs are widely used in consumer and industrial products, and emerging evidence has linked them to disruptions in lipid metabolism. In this study, urinary concentrations of five OPFR metabolites were analyzed in relation to serum levels of key omega-3 fatty acids, including eicosapentaenoic acid (EPA), docosahexaenoic acid (DHA), and docosapentaenoic acid (DPA), with adjustment for potential confounders. We observed significant negative associations between higher levels of diphenyl phosphate (DPhP) and the concentrations of EPA, DHA, and DPA. Similarly, bis(1,3-dichloro-2-propyl) phosphate (BDCPP) was negatively associated with EPA, bis(1-chloro-2-propyl) phosphate (BCEP) with DHA, and dibutyl phosphate (DBUP) with alpha-linolenic acid and DPA. Participants in the highest quartiles of DPhP and BDCPP exposure showed 18.2 and 18.4% lower EPA levels compared to the lowest quartiles, respectively. DHA levels declined by 17.5% with increasing DPhP and by 9.4% with sum of OPFRs (ΣOPFRs). These findings suggest that environmental OPFR exposure may interfere with omega-3 fatty acid metabolism and highlight potential metabolic and cardiovascular risks associated with these widely used flame retardants. These results underscore the importance of continued environmental monitoring and research into the health effects of OPFRs, particularly as their global use and human exposure continue to rise.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.